Onconase: A ribonuclease with antitumor activity Małgorzata Zwolińska 1, Piotr Smolewski 2 1 - Klinika Hematologii 2 - Zakład Hematologii Doświadczalnej Katedry Hematologii Uniwersytetu Medycznego w Łodzi
Postepy Hig Med Dosw 2010; 64 58-66 ICID: 905228
Article type: Review article
IC™ Value: 2.40
Abstract provided by Publisher
Onconase (ranpirnase) is a homologous protein obtained from Rana pipiens frog eggs. The activity of onconase, and particularly its antitumor effect, is strictly connected with ribonuclease (RN-ase) activity. Onconase induces cell death through the decomposition of inner cellular RNA, inhibition of protein synthesis, and inhibition of cell growth and proliferation and it also specifically triggers tumor cell apoptosis. A very important mechanisms of its cytotoxicity is also its antioxidant activity. The results of preclinical trials demonstrated a high activity of onconase against tumor cells, also those resistant to cytostatics. Moreover, onconase showed synergic activity with other commonly used anticancer drugs. Several clinical trials were performed on patients suffering from kidney, breast, and pancreatic cancers. Most recently a phase III study of onconase in patients with mesothelioma was completed. There are also ongoing phase I and II clinical trials with non-small-cell lung cancer (NSCLC).
ICID 905228 PMID 20173221 - click here to show this article in PubMed
